Mammogen co-founder and CEO Elizabeth Cormier-May is betting women with dense breasts will pay $500 for a breast cancer blood test rather than wait for insurers. Backed by a Series A of up to $30 million led by a public retirement system, the women’s health startup is building a self-pay path, courting short-staffed radiology groups and running a 2,600-woman trial to confirm company-reported results near 99%. Here’s
Forbes ·